Statin use and fatal prostate cancer: A matched case-control study

Cancer

Volumn 118, Issue 16, 2012, Pages 4046-4052

  Marcella, Stephen W ^a,b,c   David, Alice ^a   Ohman Strickland, Pamela A ^a,c   Carson, Jeffery ^b   Rhoads, George G ^a,b,c  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

cholesterol; mortality; prostate cancer neoplasms; statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; CANCER MORTALITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION;

AGED; CASE-CONTROL STUDIES; ETHNIC GROUPS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK;

EID: 84864654078     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26720     Document Type: Review

References (33)

1. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005; 94: 773-781.
2. Bjerre LM, LeLorier J,. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001; 110: 716-723.
3. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM,. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006; 24: 4808-4817.
4. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM,. Statins and cancer risk: a meta-analysis. JAMA. 2006; 295: 74-80.
5. Kuoppala J, Lamminpaa A, Pukkala E,. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008; 44: 2122-2132.
6. Taylor ML, Wells BJ, Smolak MJ,. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev. 2008; 17: 259-268.
7. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2218-2225.
8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE,. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2213-2217.
9. Murtola TJ, Tammela TL, Lahtela J, Auvinen A,. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2226-2232.
10. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006; 98: 1819-1825.
11. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005; 162: 318-325.
12. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer. 2010; 116: 3389-3398.
13. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela TL,. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008; 5: 376-387.
14. Hamilton RJ, Freedland SJ,. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol. 2008; 18: 333-339.
15. Marcella SW, Rhoads GG, Carson JL, Merlino F, Wilcox H,. Prostate-specific antigen screening and mortality from prostate cancer. J Gen Intern Med. 2008; 23: 248-253.
16. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
17. Waksberg J,. Sampling methods for random digit dialing. J Am Stat Assoc. 1978; 73: 40-46.
18. Surveillance, Epidemiology, and End Results Program. New Jersey Registry. Available at: http://seer.cancer.gov/registries/new-jersey.html. Accessed October 11, 2011.
19. Bersot TP,. Chapter 31. Drug therapy for hypercholesterolemia and dyslipidemia. In:, Brunton LL, Chabner BA, Knollmann BC, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011. Available at: http://www.accessmedicine.com/content.aspx?aID= 16669341. Accessed October 14, 2011.
20. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1335-1341.
21. Hammarsten J, Hogstedt B,. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005; 41: 2887-2895.
22. Boudreau DM, Yu O, Buist DSM, Miglioretti DL,. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control. 2008; 19: 767-774.
23. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S,. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002; 13: 262-267.
24. Agalliu I, Salinas CA, Hansten PD, Ostrander EA,. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008; 168: 250-260.
25. Alberti KG, Zimmet P, Shaw J,; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366: 1059-1062.
26. Freedland SJ, Platz EA,. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007; 29: 88-97.
27. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM,. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011; 103: 885-892.
28. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000; 60: 1541-1545.
29. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T,. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011; 47: 819-830.
30. Freeman MR, Cinar B, Lu ML,. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab. 2005; 16: 273-279.
31. Dulak J, Jozkowicz A,. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005; 5: 579-594.
32. Hoque A, Chen H, Xu XC,. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008; 17: 88-94.
33. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2001.